| 20th week of 2016 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20160136062 | COSMETIC USE OF A COLD PLASMA - The present invention relates to the cosmetic use of a cold atmospheric plasma for preventing and/or treating aesthetis disorders of the healthy scalp. | 2016-05-19 |
| 20160136063 | LONG-WEAR COSMETIC COMPOSITION - The present invention relates to a cosmetic composition comprising: (i) at least one oxide of an alkaline earth metal, (ii) at least one carboxylic acid having a pKa equal to or greater than 3.5, and (iii) an aqueous phase. The cosmetic composition according to the present invention can provide a long-wear effect, especially a long-wear makeup effect. | 2016-05-19 |
| 20160136064 | AQUEOUS OXIDIZING COMPOSITION FOR HAIR - Present invention relates to an aqueous oxidizing composition for hair which makes possible achieving homogeneous coloration of multiple damaged hair and especially provides excellent grey coverage with oxidative hair dyes. The object of the invention is an aqueous oxidizing composition for hair comprising one or more oxidizing agent, one or more polyol, one or more oil, one or more solid fatty alcohol and one or more surfactant wherein fatty alcohol to oil weight ratio is less than 1, weight ratio of surfactant to sum of fatty alcohol and oil is less than 0.25 and polyol concentration is less than or equal to 2% by weight calculated to the total of the composition | 2016-05-19 |
| 20160136065 | REMINERALISING ORAL CARE PRODUCTS - The invention provides an oral care product suitable for the remineralisation of teeth, the product comprising: (i) a first composition having a non-aqueous liquid continuous phase including a thickening agent, a humectant, and an agent for the remineralisation of teeth; the agent for the remineralisation of teeth being a mixture of a calcium source and a phosphate source which, when delivered to the teeth results in the in situ generation of hydroxyapatite on teeth; (ii) a second composition having an aqueous liquid continuous phase including a thickening agent and a humectant, the second composition comprising at least 30% by weight water (by weight based on the total weight of the second composition), and less than 2.5% by weight of phosphate source (by weight based on the total weight of the second composition); in which the second composition is stored separately from the first composition prior to usage of the product in a manner to avoid contact between the water in the second composition and the agent for the remineralisation of teeth in the first composition; and also in which the first and second compositions are adapted to be admixed and applied to the surface of the teeth for sustained contact. | 2016-05-19 |
| 20160136066 | Antiperspirant Compositions - An aqueous composition comprising an aluminium sesquichlorohydrate salt, water soluble calcium salt, and amino acid, wherein the molar ratio of water soluble calcium salt to aluminium is at least 1:40 and the molar ratio of amino acid to aluminium is at least 1:20 and methods for making such compositions having enhanced antiperspirancy performance. | 2016-05-19 |
| 20160136067 | Antifungal Deodorant - A prophylactic cream, ointment or deodorant for the prevention of the formation of yeast infections. | 2016-05-19 |
| 20160136068 | OXIDATION DYEING PROCESS IMPLEMENTING A PRETREATMENT BASED ON A COMPOSITION RICH IN FATTY SUBSTANCES AND ON METAL CATALYSTS - The present invention relates to a process for the oxidation dyeing of keratin fibres implementing: a) a step of pretreating said fibres by application to said fibres of a cosmetic composition (B) comprising: i) at least one fatty substance in an amount of greater than or equal to 10% by weight relative to the total weight of the composition (B); and ii) at least one metal catalyst; b) optionally a washing, rinsing, drying and/or rubbing-dry step; c) followed by a step of dyeing by application to said fibres of a cosmetic composition (A) comprising: i) at least one oxidation base, preferably chosen from para-phenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols, heterocyclic bases preferably comprising at least two nitrogen atoms, and addition salts thereof; ii) optionally at least one coupler; and iii) at least one chemical oxidizing agent. The dyeing process makes it possible to significantly improve the dyeing properties of the colouration, in particular in terms of selectivity, of chromaticity, and of colour intensity and uptake. The use of a composition which is rich in fatty substances, i.e. greater than 10%, and contains at least one catalyst pretreatment, before oxidation dyeing, allows a clear improvement in the dyeing properties, in particular in terms of dye uptake onto keratin fibres, of strength and of chromaticity and of selectivity of the colour. | 2016-05-19 |
| 20160136069 | OXIDATION DYEING PROCESS USING A COMPOSITION RICH IN FATTY SUBSTANCES WHICH COMPRISES METAL CATALYSTS AND COUPLERS - The subject of the present invention is a process for the oxidation dyeing of keratin fibres, in particular human keratin fibres such as the hair, implementing: a) a step of treating said fibres by application to said fibres of a cosmetic composition (A) comprising: i) at least one fatty substance in an amount of greater than 10% by weight relative to the total weight of the composition (A), at least one metal catalyst; ii) at least one coupler; iii) optionally at least one oxidation base, preferably chosen from para-phenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols, heterocyclic bases, addition salts thereof and solvates thereof; b) optionally a washing, rinsing, drying and/or rubbing-dry step; c) a step of treatment by application to said fibres of an oxidizing cosmetic composition (B) comprising at least one chemical oxidizing agent; and it being understood that steps a), b) and c) can be carried out successively a), then b), then c), or else a) then c), followed by b). The dyeing process makes it possible to significantly improve the dyeing properties of the colouration, in particular in terms of selectivity, of chromaticity, and of colour intensity and uptake. The use of a composition which is rich in fatty substances, i.e. greater than 10%, and contains at least one catalyst, as a pretreatment, before oxidation dyeing, allows a clear improvement in the dyeing properties, in particular in terms of dye uptake onto keratin fibres, of strength and of chromaticity and of selectivity of the colour. | 2016-05-19 |
| 20160136070 | METHODS AND COMPOSITIONS FOR ENHANCING SKIN PIGMENTATION - Described herein are methods and compositions useful for enhancing pigmentation, such as skin, eye and/or hair pigmentation comprising administering e.g., an NNT inhibitor or an agent that modifies redox status in a melanocyte. | 2016-05-19 |
| 20160136071 | Topical bimatoprost for promoting hair growth containing formulations - Bimatoprost, a prostamide F2 alpha analog, used alone or in combination with other prostamides, or prostaglandin analogs, in a topical manner for the promotion of hair growth in mustache, beard, chest and other androgen dependent hair growth areas in humans and animals. | 2016-05-19 |
| 20160136072 | Use of special N-methyl-N-acylglucamines in skin-cleaning agents and hand dishwashing agents - The invention relates to N-alkyl-N-acylglucamines of formula (I) suitable as a component in skin-cleaning agents and hand dishwashing agents, which comprise an aqueous surfactant system with at least one anionic surfactant, wherein, in formula (I), Ra is a linear or branched, saturated or unsaturated C | 2016-05-19 |
| 20160136073 | SUNSCREEN COMPOSITIONS CONTAINING AN ULTRAVIOLET RADIATION-ABSORBING POLYMER - Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase containing a sunscreen agent that includes a polymer composition containing a linear, ultraviolet radiation absorbing polyether, the linear, ultraviolet radiation absorbing polyether including a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier in an amount such that the composition includes about 0.5 percent by weight to about 3 percent by weight of the anionic oil-in-water emulsifier. | 2016-05-19 |
| 20160136074 | SUNSCREEN COMPOSITIONS CONTAINING AN ULTRAVIOLET RADIATION-ABSORBING POLYMER - Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase including a sunscreen agent that includes a linear, ultraviolet radiation absorbing polyether that comprises a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier and a nonionic oil-in-water emulsifier having an alcohol functional group, wherein the weight ratio of the anionic oil-in-water emulsifier to the nonionic oil-in-water emulsifier is about 12 or less and wherein the linear, ultraviolet radiation absorbing polyether is present in an amount effective to provide the composition with an SPF of about 10 or greater. | 2016-05-19 |
| 20160136075 | COMPOSITIONS AND METHODS FOR TEETH WHITENING - Disclosed herein are teeth whitening compositions generally including an oxidizing agent, and an activating agent that has an emission wavelength between about | 2016-05-19 |
| 20160136076 | RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION - Novel retinoic acid derivatives and a process for their preparation are described. | 2016-05-19 |
| 20160136077 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING AN AMINOBENZIMIDAZOLONE OXIDATION BASE AND A METAL CATALYST - The invention relates to a process for dyeing keratin fibres, comprising the use of one or more metal catalysts and of a composition (A) comprising: —one or more oxidizing agents, and —at least one aminobenzimidazole oxidation base of formula (I) in which the radicals R1 to R5 represent, independently of each other, a hydrogen atom; a halogen atom; a C1-C6 alkyl radical; a C1-C6 alkoxy radical; a C1-C6 dialkylamino radical; a carboxylic radical (—COOH); a sulfonic radical (—S03H); a phenyl radical; a sat orated or unsaturated 5- to 7-membered heterocyclic radical, comprising one or more heteroatoms chosen from N, O and S. | 2016-05-19 |
| 20160136078 | Method for Stabilizing Ascorbic Acid Derivatives and the Application Thereof - This invention discloses a method for stabilizing ascorbic acid derivatives and the application thereof. The mentioned method comprises mixing ascorbic acid derivative with a non-water-in-oil composition, and the composition comprises buffer, phosphonic acid derivative and at least one alcohol. The yellowish and degradation of ascorbic acid derivative can be efficiently decreased by the mentioned method. Moreover, the mentioned method can be used in topical composition, such as toner, serum, lotion, cream. | 2016-05-19 |
| 20160136079 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION - The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin. | 2016-05-19 |
| 20160136080 | Colloidally Stable Dispersions Based on Modified Galactomannans - The disclosed technology relates to a multi-functional additive for personal-care and cosmetic product applications, more particularly, a naturally derived multifunctional additive for use in skin-care formulations, which provides steric stabilization of pigment particles and/or emulsion droplets in aqueous compositions, good suspension-stability (i.e., against settling/creaming) of the compositions, and increased utilization of particulate, skin-care benefit agents contained in the compositions. | 2016-05-19 |
| 20160136081 | ABLATIVE, RENEWABLE, MULTI-FUNCTIONAL PROTECTIVE COATING FOR DENTAL SURFACES - An oral care composition in the form of a toothpaste, tooth gel, dentifrice, tooth powder, prophy paste, mouthwash, rinse, tooth mousse, dental floss, chewing gum, soluble oral care strip or film for direct application or attachment to an oral surface, or lozenge for combating dental caries, erosion, hypersensitivity, and/or staining that includes an orally acceptable carrier and a copolymer of a first α,β-ethylenically unsaturated phosphate compound (A); and one or more α,β-ethylenically unsaturated co-monomers, at least one of which is other than an allyl-functional co-monomer, wherein (A) is an allyl phosphate compound of formula (A): | 2016-05-19 |
| 20160136082 | Cosmetic Compositions Having Persistent Tightening Effects - Cosmetic compositions are provided, which are capable of having a tightening and/or curling effect on a human integument when applied thereto. Cosmetic compositions according to the invention typically include a cosmetically acceptable vehicle and a pH-dependent film-forming polymer of either a poly(methacrylic acid-co-methyl methacrylate) or a poly(methacrylic acid-co-ethyl acrylate). The tightening and/or curling effect of these cosmetic compositions is prolonged and substantially resistant to environmental stresses such as increased heat or humidity. | 2016-05-19 |
| 20160136083 | Personal Care Products That Do Not Contain Tetramer And/or Pentamer Cyclomethicones - The invention provides personal care products that do not contain D4 and/or D5 cyclomethicones but which do have the skin feel, spreadability, and other physical and chemical characteristics of personal care products that do contain these cyclomethicones. The products of the invention include a neopentyl polyol polyester(s) derived from neopentyl glycol, an isoparaffin(s), and a personal care formulation. Also included are replacement compositions for use in personal care products (so that D4 and D5 cyclomethicones can be excluded from the formulation) and methods of preparing personal care products and replacement compositions. | 2016-05-19 |
| 20160136084 | COMPOSITION COMPRISING A COMBINATION OF AN ACRYLIC POLYMER AND AN AMINO SILICONE - The present invention relates to a composition for treating keratin fibres, comprising at least an aqueous dispersion of hybrid hydrophobic film-forming acrylic polymer particles and at least one amino silicone and also to a process for treating keratin fibres using such a composition. | 2016-05-19 |
| 20160136085 | WATER-BASED LIQUID COSMETIC COMPOSITIONS - Disclosed are water-based wax free liquid cosmetic compositions comprising a synthetic thickening polymer, a natural thickening polymer, at least one nonionic surfactant, film forming polymers and polyurethane polymer. The ratio of the synthetic thickening polymer to the natural thickening polymer is ratio is less than or equal to 4:1. | 2016-05-19 |
| 20160136086 | COSMETIC FORMULATION - Disclosed is a topical skin composition and methods for its use. The composition can include | 2016-05-19 |
| 20160136087 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES - The present invention generally relates to compositions and methods for topical or transdermal delivery, e.g., for affecting mood states. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-05-19 |
| 20160136088 | SILICA HYDROGEL COMPOSITE - This invention relates to a silica hydrogel composite obtainable by mixing silica particles, comprising an encapsulated agent, with a silica sol, wherein obtained hydrogel composite is shear-thinning. The present invention also relates to use of the silica hydrogel composite according to the invention for an injectable, flowing or extrudable formulation. The present invention further relates to a method for preparing the silica hydrogel. | 2016-05-19 |
| 20160136089 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION - This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation. | 2016-05-19 |
| 20160136090 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHOD OF TREATMENT - This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder. | 2016-05-19 |
| 20160136091 | Orally Disintegrating Tablet - Disclosed is an orally disintegrating tablet including: (a) an active ingredient; (b) a starch with an amylose content of 20% by mass to 30% by mass and a degree of gelatinization of less than 10%; and (c) at least one inorganic excipient selected from the group consisting of magnesium silicate, calcium silicate, and synthetic hydrotalcite. The orally disintegrating tablet is a single-layer tablet or a dry-coated tablet having an inner core and an outer layer. The orally disintegrating tablet as a single-layer tablet or the outer layer of the orally disintegrating tablet as a dry-coated tablet has a crystalline cellulose content of 0% by mass to 5% by mass. | 2016-05-19 |
| 20160136092 | STEREOSPECIFIC LIPIDS FOR LOCOREGIONAL THERAPY WITH LONG-TERM CIRCULATING STIMULI-SENSITIVE NANOCARRIER SYSTEMS - The invention relates to stereospecific lipids for the locoregional therapy with long-term circulating stimuli-sensitive nanocarrier systems. A preferred embodiment thereof is a thermosensitive liposome for treating tumors, especially urinary bladder tumors and other localized tumors. | 2016-05-19 |
| 20160136093 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 2016-05-19 |
| 20160136094 | Compositions For Treating Acute, Post-Operative, or Chronic Pain and Methods of Using the Same - Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in in a subject are also disclosed herein. | 2016-05-19 |
| 20160136095 | METHODS FOR TREATING EPILEPSY OR SEIZURE DISORDERS - Provided herein are methods for treating epilepsy or seizure disorders comprising administering a composition to a subject, the composition comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. | 2016-05-19 |
| 20160136096 | INJECTABLE DELIVERY OF MICROPARTICLES AND COMPOSITIONS THEREFOR - Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation. | 2016-05-19 |
| 20160136097 | ULTRAFAST-DISINTEGRATING TABLET AND METHOD FOR MANUFACTURING SAME - An object of the present invention is to provide an orally disintegrating tablet (ultrafast-disintegrating tablet) having an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said ultrafast-disintegrating tablet without such a complicated process as freeze-drying. | 2016-05-19 |
| 20160136098 | ORALLY DISINTEGRATING EXCIPIENT - The present invention is directed to coprocessed excipient particles comprising a cellulosic material such as microcrystalline cellulose in intimate association with silicon dioxide, a disintegrant and a polyol, sugar or a polyol/sugar blend. The excipient particles display good processing and are useful in prepared compressed solid dosage forms that exhibit rapid disintegration (less than about 60 seconds) when placed on the tongue or when tested according USP disintegration testing, while still providing acceptable mouth feel. | 2016-05-19 |
| 20160136099 | METHOD FOR PRODUCING MONOLITHIC TABLETS - The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash. | 2016-05-19 |
| 20160136100 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME - A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber. | 2016-05-19 |
| 20160136101 | GASTRO-RESISTANT SOFT SHELL CAPSULE AND PROCESS FOR ITS MANUFACTURE - The invention relates to gastro-resistant soft shell capsules having a capsule shell comprising high acyl gellan gum, at least one starch and at least one plasticizer, wherein the capsules fulfil pharmacopoeial disintegration tests characterizing the capsules as gastro-resistant dosage forms. The invention further relates to a method for manufacturing such gastro-resistant soft shell capsules. | 2016-05-19 |
| 20160136103 | Pharmaceutical Composition in the Form of Granules for the Treatment of Metabolic Disorders in Children - The present invention relates to a pharmaceutical composition for pediatric use and having controlled release, for treating metabolic disorders involving urea in children, said composition being in the form of granules behaving like a pseudofluid, said granules including a core consisting of sucrose, cellulose or isomalt particles, and of at least one active ingredient, said active ingredient having a water solubility of 200 g/L to 630 g/L of water, and at least one coating agent covering said core, the mean diameter of the microgranules being 0.1 mm to 1.2 mm and the granules having an angle of repose of less than 30. | 2016-05-19 |
| 20160136104 | WIRELESS COMMUNICATIONS SYSTEM INTEGRATING ELECTRONICS INTO ORALLY INGESTIBLE PRODUCTS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS - Various embodiments of the present disclosure include a consumable capsule containing an active ingredient in at least one compartment movably sealed by a stimuli responsive actuator, and an activation device configured to communicate with the consumable capsule. The activation device is configured to emit a wireless signal to activate the stimuli responsive actuator of the consumable capsule, and the consumable capsule is configured to release the active ingredient into an external environment based on the activation of the stimuli responsive actuator. | 2016-05-19 |
| 20160136105 | Compositions and Methods for the Delivery of Therapeutics - The present invention provides compositions and methods for the delivery of antivirals to a cell or subject. | 2016-05-19 |
| 20160136106 | Nanoparticles Leverage Biological Membranes to Target Pathogens for Disease Treatment and Diagnosis - Provided are methods, combinations and pharmaceutical compositions for treating or preventing an infection in a subject using a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane configured for adhesion of a pathogen that causes said infection. Exemplary infection includes infection caused by a virus, bacterium, fungus, or protozoan. | 2016-05-19 |
| 20160136107 | STORAGE STABLE TRANSDERMAL PATCH OF ROTIGOTINE - Disclosed is a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and the release liner, the adhesive layer comprising an active agent solubilized in an adhesive matrix, the adhesive matrix comprising a mixture of biocompatible polymers, wherein the active agent is soluble in at least one of the biocompatible polymers. | 2016-05-19 |
| 20160136108 | HYDROXYTYROSOL COMPOSITIONS FOR TREATMENT OF CARTILAGE INJURIES IN JOINTS - The invention relates to the use of hydroxytyrosol for inducing or enhancing cartilage repair or cartilage regeneration. Furthermore, the invention relates to nutraceutical and pharmaceutical compositions comprising hydroxytyrosol for regeneration and repair of cartilage injuries in joints, in particular of traumatic cartilage injuries. | 2016-05-19 |
| 20160136109 | COMPOSITIONS FOR TISSUE STABILIZATION - Collagen crosslinking/stabilization composition optionally in combination with elastin crosslinking composition as treatment of vascular aneurysms, methods of using the compositions, especially with respect to in vivo procedures are described. The treatment is achieved through the delivery of an effective amount of crosslinking/stabilization composition to the site of the aneurysm. The crosslinking/stabilization agent may be embedded in a delivery composition and delivered to the site of aneurysm using a delivery device. The site of the aneurysm may be isolated for treatment using the delivery device. The elastin stabilization agent may be simultaneously or sequentially delivered with the collagen crosslinking/stabilization agent for the treatment of vascular aneurysms in the isolated section of blood vessel. | 2016-05-19 |
| 20160136110 | Method for Treating a Neurodegenerative Event - A method of neuroprotection or treating or healing a wound, orifice, surgical site or a neurodegenerative event in an individual or animal via modulation of at least one neurotrophin by administering a therapeutically effective amount of at least one fatty acid amide hydrolase (FAAH) inhibitor or a physiologically acceptable salt thereof to the individual or animal. Administration of the at least one FAAH inhibitor may be via release from an article of manufacture that includes a support. | 2016-05-19 |
| 20160136111 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 2016-05-19 |
| 20160136112 | COMPOSITION COMPRISING TAPENTADOL IN A DISSOLVED FORM - The present invention relates to a composition comprising tapentadol in a dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising tapentadol in a dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention. Finally, the invention relates to the use of a saturated tapentadol solution for the preparation of a solid oral dosage form. | 2016-05-19 |
| 20160136113 | TOPICAL VASOCONSTRICTOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided. | 2016-05-19 |
| 20160136114 | METHOD FOR THE TREATMENT OF DRAVET SYNDROME - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2016-05-19 |
| 20160136115 | T TYPE CALCIUM CHANNEL INHIBITORS - The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R | 2016-05-19 |
| 20160136116 | Carmustine Pharmaceutical Composition - The present invention provides pharmaceutical formulations of lyophilized carmustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized carmustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with carmustine, such as neoplastic diseases. | 2016-05-19 |
| 20160136117 | BOLUS DOSE OF HYDROXYCITRIC ACID WITH GLYCEROL - A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required. | 2016-05-19 |
| 20160136118 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A COMMON COLD AND SYMPTOMS THEREOF - Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of a common cold, utilizing various methods of administration od X-ray contrast media (CM). | 2016-05-19 |
| 20160136119 | DP2 ANTAGONIST AND USES THEREOF - Described herein is the DP | 2016-05-19 |
| 20160136120 | TRANSDERMAL DELIVERY KITS - Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen, and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens. | 2016-05-19 |
| 20160136121 | USE OF CILASTATIN TO REDUCE THE NEPHROTOXICITY OF DIFFERENT COMPOUNDS - Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects. | 2016-05-19 |
| 20160136122 | METHODS FOR TREATING PSORIATIC ARTHRITIS - Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein. | 2016-05-19 |
| 20160136123 | TREATMENT OF AUTOPHAGY-RELATED DISORDERS - The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions. | 2016-05-19 |
| 20160136124 | ADMINISTRATION OF A FOOD COMPOSITION PRODUCT - Method for orally administrating a subject a food composition product, referred to as “Preload Meal,” before administering a main meal to the subject. The food composition product includes nutrients that stimulate the release of incretins in the subject prior to administration of the main meal, increasing satiety, lowering total energy intake from both the food composition product and the main meal, and contributing to a biological control of a post prandial blood sugar level and a post prandial insulin level in the subject. | 2016-05-19 |
| 20160136125 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONSCOMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 2016-05-19 |
| 20160136126 | Pharmaceutical compositions of Anisomelic acid and the use thereof - A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided. | 2016-05-19 |
| 20160136127 | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR INCREASING RADIOSENSITVITY IN THE TREATMENT OF A BRAIN TUMOUR - The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma. | 2016-05-19 |
| 20160136128 | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA - The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG. | 2016-05-19 |
| 20160136129 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. | 2016-05-19 |
| 20160136130 | Oral Ultraviolet Resistance Enhancer - To provide an ultraviolet resistance enhancer capable of enhancing resistance of the skin to ultraviolet rays by oral ingestion, thereby reducing or suppressing skin damages caused by exposure to ultraviolet rays. An oral ultraviolet resistance enhancer comprising glucono-δ-lactone as an active ingredient. | 2016-05-19 |
| 20160136131 | FORMULA COMPRISING A HYPOLIPIDEMIC AGENT - The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. | 2016-05-19 |
| 20160136132 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA - The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor. | 2016-05-19 |
| 20160136133 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES - The present invention relates to the use of indolinones of general formula | 2016-05-19 |
| 20160136134 | ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR - Provided are compounds antiviral compounds represented by formula Ia and Ib: | 2016-05-19 |
| 20160136135 | METHOD OF TREATMENT OF CNS DISORDERS - The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity. | 2016-05-19 |
| 20160136136 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF SYNAPSE FUNCTION - Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease. | 2016-05-19 |
| 20160136137 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION - The present invention relates to methods for treating acne and other skin infections caused or mediated by | 2016-05-19 |
| 20160136138 | DRUG FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE - The present invention provides a compound useful in the prevention and treatment of nonalcoholic fatty liver disease. The invention relates to a drug for the prevention and/or treatment of nonalcoholic fatty liver disease, the drug having as an active ingredient (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of these. | 2016-05-19 |
| 20160136139 | ITE FOR CANCER INTERVENTION AND ERADICATION - A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment. | 2016-05-19 |
| 20160136140 | Chemical Compounds - The invention concerns compounds of Formula (I) | 2016-05-19 |
| 20160136141 | RIFAXIMIN READY-TO-USE SUSPENSION - A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension. | 2016-05-19 |
| 20160136142 | TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-C]PYRIDINES - Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula I | 2016-05-19 |
| 20160136143 | COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder. | 2016-05-19 |
| 20160136144 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering a 1-aminocyclohexane derivative such as memantine and an acetylcholinesterase inhibitor (AChEI) such as donepezil. | 2016-05-19 |
| 20160136145 | BITOPIC MUSCARINIC AGONISTS AND ANTAGONISTS AND METHODS OF SYNTHESIS AND USE THEREOF - Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of M | 2016-05-19 |
| 20160136146 | COMPOSITIONS AND METHODS FOR TREATING PRIMARY EFFUSION LYMPHOMA - Methods for treating primary effusion lymphoma (PEL) are provided. The methods include administering to a patient in need thereof an effective amount of an immunomodulatory compound. Suitable immunomodulatory compounds include compounds having the formula: | 2016-05-19 |
| 20160136147 | EXTENDED RELEASE NICOTINAMIDE FORMULATION - The invention provides various extended release granules of nicotinamide. Granule properties can be enhanced by the inclusion of a conductive filler. | 2016-05-19 |
| 20160136148 | SOLID DISPERSIONS OF AMORPHOUS PAROXETINE MESYLATE - The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a-vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient. Methods for the treatment using paroxetine mesylate in the form of a solid dispersion according to the invention are also disclosed. | 2016-05-19 |
| 20160136149 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2016-05-19 |
| 20160136150 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK - The present invention relates to compounds of formula I: | 2016-05-19 |
| 20160136151 | Orvinol and Thevinol Derivatives Useful in the Treatment of Anxiety or a Compulsive Disorder - The invention provides a method of treating anxiety or a compulsive disorder in a subject comprising administering to the subject a compound having formula 2: | 2016-05-19 |
| 20160136152 | OXYMORPHONE CONTROLLED RELEASE COMPOSITIONS - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 2016-05-19 |
| 20160136154 | EXTENDED RELEASE HYDROCODONE ACETAMINOPHEN AND RELATED METHODS AND USES THEREOF - The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily. | 2016-05-19 |
| 20160136155 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects - This disclosure relates to methods of increasing the metabolic lifetime of dextromethorphan administering threohydroxybupropion or bupropion to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or bupropion are also disclosed. | 2016-05-19 |
| 20160136156 | IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING OXYCODONE AND NALOXONE - The present invention pertains to oral immediate release pharmaceutical compositions suitable for treating patients suffering from pain comprising oxycodone and naloxone or their pharmaceutically acceptable salts. | 2016-05-19 |
| 20160136157 | INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions. | 2016-05-19 |
| 20160136158 | PLATINUM COMPOUNDS THAT INHIBIT CONSTITUTIVE STAT3 SIGNALING AND INDUCE CELL CYCLE ARREST AND APOPTOSIS OF MALIGNANT CELLS - The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention. | 2016-05-19 |
| 20160136159 | Method for Treating Peripheral Neuropathy - A method of treating or preventing peripheral neuropathy in a subject determined to be in need thereof comprising: topically administering to the subject an anti-peripheral neuropathic compound acting as GFRα3 type receptor agonist. | 2016-05-19 |
| 20160136160 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-II - The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy by administering to a subject N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-(piperazin-1-yl)-4-o-tolyl nicotinamide or 4-alkyl-piperazin-1-yl derivatives thereof. | 2016-05-19 |
| 20160136161 | Use of Flibanserin in the Treatment of Obesity - The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof. | 2016-05-19 |
| 20160136162 | COMPOSITIONS AND METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING - Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. | 2016-05-19 |
| 20160136163 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE-SULFAMIDE - The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof | 2016-05-19 |
